Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VGX-1027 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | 40mg QD dose group |
| Group 2 | EXPERIMENTAL | 100mg QD dose group |
| Group 3 | EXPERIMENTAL | 200mg QD dose group |
| Group 4 | EXPERIMENTAL | 200mg BID dose group |
| 1 | EXPERIMENTAL | 1mg dose group |
| 2 | EXPERIMENTAL | 10mg dose group |
| 3 | EXPERIMENTAL | 100mg dose group |
| 4 | EXPERIMENTAL | 200mg dose group |
| 5 | EXPERIMENTAL | 400mg dose group |
| 6 | EXPERIMENTAL | 800mg dose group |
| Name | Type | Description |
|---|---|---|
| VGX-1027 | DRUG | Subjects will |
Inclusion Criteria: * Must give written informed consent. * Healty subjects as determined by no clinically significant deviation from normal as judged by the investigator in medical history, physical examination, ECGs and clinical laboratory evaluations. * Body Mass Index (BMI) of 18 to 30kg/m2 ±0....
VGX-1027 is an investigational small molecule being developed by Inovio Pharmaceuticals, Inc. (NASDAQ: INO). It is currently in Phase 1 clinical development and has been studied in healthy volunteers to evaluate its safety and pharmacokinetic profile.
VGX-1027 is being studied for use in healthy subjects as part of early-phase clinical trials. The completed Phase 1 trials focused on assessing the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers, rather than treating a specific disease.
VGX-1027 is developed by Inovio Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol INO. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetic properties in healthy subjects.
VGX-1027 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving healthy volunteers. The drug remains investigational and has not been approved by regulatory authorities for any use.
VGX-1027 has been studied in two completed Phase 1 trials: NCT00627120, a single-dose safety and pharmacokinetic study in 48 healthy subjects, and NCT00760396, a multiple-dose study in 40 healthy subjects. Both trials were conducted in the United States and enrolled adults aged 18 years and older.
No alternative names for VGX-1027 have been disclosed. The drug is identified solely by its code name VGX-1027 in the clinical trial records and by the developer, Inovio Pharmaceuticals.